Abstract Library

#4367 Comparative analysis of post-pancreatic surgical complications in elderly versus younger patients with inactive neuroendocrine pancreatic tumours

Introduction: The management of small, asymptomatic non-functional pancreatic neuroendocrine neoplasms (NF-pNENs) is contentious, with two main approaches: surgical resection and "watch-and-wait." Current guidelines recommend monitoring NF-pNENs under 2 cm based on retrospective data, although recent U.S. studies suggest improved survival with surgery for 1-2 cm NF-pNENs. Some suggest the "watch-and-wait" approach for older patients, though its efficacy is unclear.

Conference:

Presenting Author: Zamparas A

Authors: Zamparas A, Aghamaliyev U, Seidel G, Meyer Y, Werner J,

Keywords: nf-pnen, popf, pancreatic surgery, pNEN, pancreas,

#4301 Case report on the effectiveness of combination therapy in highly aggressive resistant prolactinoma

Introduction: Prolactinomas represent 50% of pituitary neuroendocrine tumours (PitNET), aggressive prolactinomas represent 15% of them.

Conference:

Presenting Author:

Authors: Asanova A, Shutova A, Pigarova E, Dzeranova L,

Keywords: prolactinoma, IHC, Pit Net, chemotherapy,

#3992 Recurrence free survival and disease-specific survival in patients with pancreatic neuroendocrine neoplasms: A single center retrospective study of 413 patients

Introduction: The prognosis and impact of different prognostic factors in pancreatic neuroendocrine neoplasms (pNEN) remains controversial.

Conference:

Presenting Author: Andreassen M

Authors: Møller S, Langer S, Slott C, Krogh J, Palnæs Hansen C,

Keywords: Pancreatic neuroendocrine neoplasms incidence, clinical presentation, prognosis,

#3958 Treatment strategy for pancreatic NETs smaller than 2 cm should be based on the diagnosis of malignancy as well – New treatment strategy for small pancreatic NETs

Introduction: There are still many unclear issues regarding the treatment of non-functioning small (≤20 mm) pancreatic neuroendocrine neoplasms (pNENs).

Conference:

Presenting Author: Hijioka S

Authors: Hijioka S, Yamashige D, Esaki M, Honda G, Masui T,

Keywords: small pancreatic neuroendocrine neoplasm, tumor size, grading, treatment strategy, Japanese cohort,

#3818 Somatostatin analogues or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors

Introduction: Non-functioning (NF), sporadic, G1-G2 pancreatic neuroendocrine tumors (PanNETs) usually display an indolent course. Surgery is the first-choice treatment for localized tumors >2 cm. Unresectable or metastatic PanNETs expressing somatostatin receptors (SSTRs) are treated with somatostatin analogues (SSAs). The PROMID and the CLARINET studies proved the SSA antiproliferative effect in advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The standard treatment for patients with PanNETs ≤2cm is active surveillance (AS). Yet no evidence of the value of SSA treatment exist in such patient population.

Conference:

Presenting Author: Maratta M

Authors: Maratta M, Chiloiro S, Raia S, Maiorano B, Rossi E,

Keywords: PanNET, somatostatin analogues, efficacy, surveillance, medical treatment,